By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genocea Biosciences 

100 Acorn Park Drive

Cambridge  Massachusetts  02140  U.S.A.
Phone: 617-876-8191 Fax: 617-876-8192


Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases.

Genocea’s pipeline includes programs addressing genital herpes, pneumococcus, chlamydia, malaria and cancer immunotherapy. We currently have two products in Phase 2 clinical development:

• GEN-003, an immunotherapy to treat patients with genital herpes. We reported positive top-line data from an ongoing Phase 2b dose optimization trial from the immediate post dosing 28-day observation period in May 2015. We identified an improved dose of 60µg per protein/75µg of adjuvant, which demonstrated a highly statistically significant reduction (p>0.0001) from baseline in the viral shedding rate (55%) and genital lesion rate (60%). Data from the six-month and 12-month observation periods in this trial is expected in the fourth quarter of 2015 and the first quarter of 2016, respectively.

Data from the prior Phase 1/2a trial was the first time a therapeutic vaccine candidate has demonstrated significant reductions in the rates of viral shedding and genital lesions in genital herpes patients.

• GEN-004, a universal vaccine which is in Phase 2 development to prevent infections caused by all serotypes of pneumococcus. We have completed enrollment in a Phase 2 human challenge clinical trial and expect to report top-line data in the fourth quarter of 2015.

In a prior Phase 1 study, GEN-004 met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces.

Key Statistics

Ownership: Public

Web Site: Genocea Biosciences
Symbol: GNCA

Company News
Genocea Biosciences Reports Second Quarter 2015 Financial Results 8/6/2015 12:27:21 PM
Genocea Biosciences Announces Closing Of $50 Million Public Offering Of Common Stock 8/4/2015 10:58:39 AM
Genocea Biosciences To Host Second Quarter 2015 Financial Results Conference Call & Webcast On August 6, 2015 7/31/2015 10:14:09 AM
Genocea Biosciences Announces Pricing Of $50 Million Public Offering 7/30/2015 11:09:52 AM
Genocea Biosciences Announces Positive Top-Line Phase 2 Data For Genital Herpes Immunotherapy GEN-003 5/20/2015 12:02:33 PM
Genocea Biosciences To Present At The UBS Global Healthcare Conference 5/13/2015 11:24:55 AM
Genocea Biosciences Reports First Quarter 2015 Financial Results 5/7/2015 12:58:22 PM
Genocea Biosciences To Host First Quarter 2015 Financial Results Conference Call & Webcast On May 7, 2015 5/1/2015 9:44:31 AM
Genocea Biosciences Completes Enrollment In Phase IIa Human Challenge Study Of GEN-004 For The Prevention Of Infection By Pneumococcus 4/22/2015 8:34:07 AM
Genocea Biosciences To Present At The 14th Annual Needham & Co. Healthcare Conference 4/8/2015 10:00:56 AM